Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

35 126

Cited 1551 times in

Authors: Masao Omata ; Ann-Lii Cheng ; Norihiro Kokudo ; Masatoshi Kudo ; Jeong Min Lee ; Jidong Jia ; Ryosuke Tateishi ; Kwang-Hyub Han ; Yoghesh K Chawla ; Shuichiro Shiina ; Wasim Jafri ; Diana Alcantara Payawal ; Takamasa Ohki ; Sadahisa Ogasawara ; Pei-Jer Chen ; Cosmas Rinaldi A Lesmana ; Laurentius A Lesmana ; Rino A Gani ; Shuntaro Obi ; A Kadir Dokmeci ; Shiv Kumar Sarin

MeSH: Asia ; Carcinoma, Hepatocellular / epidemiology* ; Carcinoma, Hepatocellular / therapy ; Carcinoma, Hepatocellular / virology ; Coinfection / epidemiology ; Disease Management ; Evidence-Based Medicine ; Hepatitis B / epidemiology* ; Hepatitis B / therapy ; Hepatitis C / epidemiology* ; Hepatitis C / therapy ; Humans ; Liver Neoplasms / epidemiology* ; Liver Neoplasms / therapy ; Liver Neoplasms / virology ; Meta-Analysis as Topic ; Practice Guidelines as Topic

Keywords: APASL ; Asia–Pacific ; Hepatocellular carcinoma ; Treatment algorithm

Abstract: There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia-Pacific region, where HCC is one of the leading public health problems. Since the "Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines" meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia-Pacific region, which has a diversity of medical environments.